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Italian-THAlassemia-Cosy-&-Outcomes-Assessment (ITHACA)
was a naturalistic multicentre study conducted to evaluate costs,
quality of life, compliance and treatment satisfaction in MT
patients undergoing ICT. In total 126 MT patients >12 years old
completed a 28-item satisfaction instrument consisting of 4
domains (perceived effectiveness, burden, side effects, accep-
tance. Response continuum ranged from 1 (very dissatisﬁed) to
5 (very satisﬁed). RESULTS: The median age was 29.4 years
(12.3–48.5), with an equal proportion of males and females. At
enrolement, 48.0% were treated with Deferoxamine, 33.6%
with Deferiprone and 18.4% with combination treatment.
86.5% of patients had at least one MT-related complication and
13.5% changed treatment regimens at least once during the
observational period (11.6 median months). Mean satisfaction
scores for “acceptance”, “side effects”, “burden” and “perceived
effectiveness” were 3.37, 3.57, 3.87 and 4.29 respectively. Simple
linear regression analysis showed that satisfaction with “accep-
tance” (R2 = 11%), “burden” (R2 = 13%) and “side effects”
(R2 = 12.3%) are signiﬁcantly and positively associated with the
adherence item “never thinking about stopping medication” 
(p < 0.0001 in both cases). CONCLUSIONS: The level of satis-
faction with “burden”, “acceptance” and “side effects” in MT
patients undergoing ICT can help to predict patient adherence.
Strategies able to improve satisfaction with ICT are expected to
increase patients’ adherence, with potential signiﬁcant conse-
quences on treatment effectiveness.
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OBJECTIVES: New anticoagulant drugs, alternative to vitamin
K antagonist (VKA) are currently under clinical evaluation.
Patients’ preferences should be considered in the development of
new therapeutic strategies. Objective of this study was to elicit
patients’ preferences on different treatment options. METHODS:
A discrete-choice-exercise (2 different scenarios in 9 pair-wise
comparisons) was applied to consecutive patients of all ages on
stable OAT or during their OAT starting-visit. The following
attributes were considered to be important after interviewing 20
patients and 6 physicians: route and number of administrations,
monitoring frequency, minor bleedings (few vs. no), treatment
out-of-pocket payment (€0 vs. €15 vs. €75/month), drugs/food
interactions and dose-adjustment (required vs. not-required). The
Possible relationship between sociodemographic and/or clinical
characteristics of the respondents and their preferences were eval-
uated. RESULTS: The questionnaire was completed by 237
patients (55%male; mean-age = 63/ds = 14; 41%on-stable-OAT).
A signiﬁcant monetary discrimination was reached for all attrib-
utes, except “interactions” and “dose adjustment”. The condi-
tional-probit-model demonstrated that patients are willing-to-pay
(WTP) per month: €79 for once-daily administration-tablets vs
one subcutaneous weekly-injection; €41 for once-daily adminis-
tration-tablets vs. twice-daily administration-tablets; €21 for
once-monthly vs. twice-monthly; €18 for each 6 month vs. once-
monthly visits; €23 for a drug without bleeding-risk. The model
showed important differences between stable and starting OAT
patients: the WTP for less frequent monitoring and no interac-
tions is greater for patients in stable-OAT; the WTP to avoid bleed-
ings is greater for starting patients. Also the employment status
matters: employed patients are more willing to pay for a treat-
ment with less frequent monitoring. CONCLUSIONS: To our
knowledge, this study is the ﬁrst to elicit preferences from patients
in OAT. The importance of this study is the achievement of
patient’s preferences in a simply and well accepted method to
allow planning optimal health care.
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THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
(BPH) IN POLAND
Dardzinski W1, Pawlik D1, Walczak J1,Wojcik R1, Kaczor M1,
Nogas G1, Glogowski C2, Cel M2
1Arcana Institute, Cracow, Poland, 2GSK Commercial Sp. z o.o,
Warsaw, Poland
OBJECTIVES: To estimate impact of dutasteride reimbursement
on budget from the perspective of National Health Fund (NHF)
in Poland. METHODS: Decision-analytic model was developed
to assess budget impact of dutasteride. Costs and resource use
are from published literature and NHF catalogue of procedures.
Costs of drugs, surgical intervention and prostate cancer treat-
ment were taken into account. Clinical data, including compli-
cations and prostate cancer rates, were obtained from the clinical
effectiveness analyses of dutasteride. Budget impact analysis was
performed in four different scenarios with regard to reimburse-
ment reference price and rates (Scenario 1: 50% reimbursement
rate, reference price = reference price for Penester; Scenario 2:
50% reimbursement rate, reference price = Avodart price; Sce-
nario 3: 70% reimbursement rate, reference price = reference
price for Penester; Scenario 4: 70% reimbursement rate, refer-
ence price = Avodart price). RESULTS: In case of Avodart (dutas-
teride) reimbursement, NHF would save: 65,888–562,612 PLN
in year 1, 197,664–1,687,836 PLN in year 2, 300,477–
2,625,523 PLN in year 3 and 376,229–3,212,590 PLN in year
4 and later, depending on assumed reimbursement reference price
and rate. CONCLUSIONS: Reimbursement of dutasteride
would result is savings from the perspective of the National
Health Fund in Poland.
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OBJECTIVE: The choice is between two types of hormones used
for follicle stimulation in IVF treatment—recom-binant FSH
(rFSH) and the urine-derived menotrophin. A literature review
by NICE in the UK carried out in 2004 documented that the two
types of hormones were equally effective and safe consequently
it was recommended to use the cheaper menotrophin. Based on
ﬁndings by the European and Israeli Study Group (EIGS), the
objective was to analyse the health economic consequences of
this choice between the two types of hormone in IVF treatment
in Denmark. METHODS: Based on the EISG study a prospec-
tive cost-effectiveness analysis, which compared menotrophin
(Menopur®) and rFSH (Gonal-F®), was carried out. The analy-
sis had a health care sector perspective with the inclusion of costs
of hormone stimulation, visits, ultrasound, IVF, ICSI and inpa-
tient stay at the hospital. Danish unit costs (2005) were applied.
Differences in costs were compared with differences in effects to
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measure cost-effectiveness. RESULTS: The total costs for the
average patient are lower when using menotrophin (DKK
13,324; 95%CI: 12,583–14,282) compared with rFSH (DKK
15,852; 95%CI: 15,164–16,614). Furthermore, the cost per clin-
ical pregnancy was lower with menotrophin (DKK 59,282;
95%CI: 50,207–72,056) compared with rFSH hormone (DKK
82,474; 95%CI: 68,389–102,867). Menotrophin is therefore less
expensive both to the patient as well as to the health care sector.
A result which was supported by a bootstrap analysis with 1000
replications. Use of menotrophin can result in savings up to 16
million DKK on the drug budget per year. Savings that could
ﬁnance 1400 additional IVF cycles. CONCLUSION: The analy-
sis has shown that menotrophin compared with rFSH is a cost-
effective choice that is rational to the society and to the health
care sector leading to savings to the patient and the drug budget.
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OBJECTIVES: RIX4414, an oral live-attenuated human
rotavirus (RV) vaccine, has shown to be highly protective against
RV gastroenteritis. The question rises whether the implementa-
tion of vaccination is a cost-effective (CE) management strategy.
METHODS: An economic modelling exercise was performed to
evaluate the CE of vaccination in a Belgian setting. The model
used a Markov process tree, the cycle length was one month with
a lifetime horizon. Effect of seasonality of the infection and of
breastfeeding protection was captured through the model. Acute
diarrhoea events were recorded until the age of 5. Assumed was
that the risk for acute RVGE rapidly decreases after age 5 due
to the acquired natural immunity. Estimates on RV epidemiol-
ogy were obtained from Belgian databases and literature. QALY
was the overall effect measure. Utility-score estimates for age-
groups and health states were obtained through the EQ-5D from
a UK study. The vaccine effect was as reported from phase IIIb
European trial (102247-NTC0014686). Annual discount rates
for cost and effect measures were 3% and 1.5%, respectively.
100% coverage was assumed in base-case analysis but sensitiv-
ity analyses were performed on key variables in the model.
RESULTS: The model estimated the direct medical cost (DMC)
at around €6.75 million/year (hospitalisation costs accounted for
64%), whilst indirect costs accounted for an additional €12
million/year. Threshold for being CE was set at ≤€50,000/QALY.
The analysis indicated that over a lifetime horizon vaccination
with RIX4414 is cost-effective including only DMC (€77.4/
dose). This strategy with the same price/dose induced cost
savings when also indirect costs were included in the equation.
Sensitivity analysis indicated that when emergency visits and hos-
pitalisation rates were substantially reduced (<20%) vaccination
was cost-effective when DMC and indirect costs were consid-
ered. CONCLUSIONS: RIX4414 vaccination is a cost-effective
strategy in a Belgian environment selecting a wide variety of sce-
narios in a societal perspective.
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THE COST EFFECTIVENESS OF IVF IN ITALY: IMPLICATIONS
OF A NEW LAW
Dale PL
United BioSource Corporation, London, UK
OBJECTIVES: The Italian government recently banned embryo
cryopreservation for in vitro fertilization (IVF). The objective of
this study was to compare the cost effectiveness of IVF with 
and without the option of embryo freezing over three cycles of 
IVF from the Italian NHS perspective. METHODS: A decision 
analytical model was developed to evaluate the cost and cost-
effectiveness of two potential treatment approaches in couples
attempting IVF: (A) To perform three IVF fresh cycles including
the option of frozen embryo transfer; and (B) To perform three
IVF fresh cycles with no frozen embryo transfer. No treatment
was used as the reference strategy. Efﬁcacy data were derived
from clinical trials and the Italian IVF registry. A micro-costing
approach was used to determine the cost of fresh and frozen IVF
cycles. Drug costs and hospitalization costs were derived from
published sources. The primary outcome was measured in terms
of a live birth. Uncertainty surrounding the CE ratio was tested
using one-way sensitivity analysis. RESULTS: The model pre-
dicted a cumulative live birth rate after three completed IVF
cycles of 30.9% in the strategy using cryopreservation compared
to 25.3% in the IVF without cryopreservation approach. The
total cost per treatment was €4905 with the no frozen embryo
transfer strategy versus €5453 for the frozen embryo transfer.
The strategy to perform IVF without cryopreservation was
extensively dominated by the combination of no treatment and
IVF plus cryopreservation strategies. The incremental cost per
additional live birth was €21,863 for the IVF with embryo cry-
opreservation compared to the no treatment alternative. Results
were most sensitive to variations in the cost of an IVF treatment
cycle. CONCLUSIONS: Providing three cycles of IVF with the
frozen embryo option on the National Health Service in Italy
compares favorably to the option of allowing infertile couples
only three cycles of IVF.
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OBJECTIVES: To compare the clinical and cost-effectiveness of
dutasteride with placebo and ﬁnasteride in BPH. METHODS:
Systematic review according to Cochrane Collaboration guide-
lines and clinical effectiveness analysis according to Polish Phar-
macoeconomic Guidelines were performed. In the absence of
relevant head-to-head RCT dutasteride vs ﬁnasteride on clinical
hard endpoints, meta-analysis was performed using an indirect
comparison, with placebo as the common reference (Bucher
method). Cost-effectiveness Markov model was performed from
payer perspective (health insurance), using costs data from pub-
lished sources and a lifetime horizon. RESULTS: Dutasteride vs
placebo: 3 clinical trials were included. Dutasteride treatment
was associated with statistically signiﬁcantly greater reduction in
urological symptoms (AUA-SI scale) compared to placebo, with
difference in changes of 1.1, 1.4 and 2.2 points after 12, 18 and
24 months, respectively. There was statistically signiﬁcant dif-
ference in BPH Impact Index after 6 months (p < 0.005) and
after 24 months of follow-up (p < 0.001). Dutasteride signiﬁ-
cantly reduced risk of acute retention of urine (OR = 0.42),
prostate cancer (OR = 0.56) and necessity of surgical interven-
tion (OR = 0.51). Average costs (including costs of drugs, com-
plications and prostate cancer treatment) and effects (life-years
with no surgery/prostate cancer) were: dutasteride 5298 PLN/8
LY; placebo 2426 PLN/6.25 LY. ICER for dutasteride vs placebo
comparison was 1645 PLN/LY without surgery/Prostate cancer.
Dutasteride vs ﬁnasteride: 12 trials were included (1 direct and
